Teva Pharmaceuticals: 37% Improvement In Net Income Year Over Year

|
About: Teva Pharmaceutical Industries Limited (TEVA)
by: Faloh Investment
This article is exclusive for subscribers.
Faloh Investment
Long/short equity, Deep Value, special situations
Summary

The stock's recovery has almost entirely reversed as the price per share returns nearer to all-time lows.

Management anticipates over $3.5B free cash flow for 2018.

A big challenge for the business is paying off another $29B in long-term debt. The target looks achievable now that we're seeing stabilization across product segments.

Teva Pharmaceutical Industries Limited (TEVA) is trading for $14.92 per share at a market cap of $16.19B. Price action in this name has investors watching the stock brick since September of this year